Inovio Pharmaceuticals

Inovio Pharmaceuticals

Inovio Pharmaceuticals, headquartered in Plymouth Meeting, Pennsylvania, is a clinical-stage biotechnology company focused on developing DNA medicines. Jacqueline Shea, a biotech executive, serves as President and CEO; Laurent Humeau, Ph.D., is Chief Scientific Officer. The company's platform uses synthetic DNA constructs delivered via its proprietary CELLECTRA® electroporation device to produce antigens or antibodies in the body. The firm's pipeline targets HPV-related diseases, cancers, and infectious diseases. Lead candidate INO-3107, for recurrent respiratory papillomatosis (RRP), a rare HPV-related respiratory disease, has a Biologics License Application (BLA) accepted for FDA review (per the firm, 2026). Earlier-stage programs include therapies for HPV-positive head and neck cancer and prostate cancer. Inovio's platform replaces chemical adjuvants, lipid nanoparticles, or viral vectors with electroporation-mediated delivery, aiming for sustained protein expression and T-cell generation. The company operates research and device engineering facilities in San Diego, California, alongside its Pennsylvania headquarters. The firm's clinical pipeline spans multiple candidates, with INO-3107 as the most advanced. Additional therapeutic candidates include next-generation DNA medicine technologies targeting oncology and infectious disease. The team includes Michael Sumner, M.D., as Chief Medical Officer, Peter Kies as CFO, and Steve Egge as Chief Commercial Officer — the latter focused on commercialization planning. Inovio has established partnerships with academic and industry collaborators to advance its platform, though details of specific partners are not publicly detailed. Inovio's structural differentiator is its DNA medicine platform and CELLECTRA® delivery system — a non-viral, non-lipid-nanoparticle approach that sets it apart from RNA and viral-vector therapies. This architecture, rooted in electroporation technology, is designed to enable repeat dosing without anti-vector immunity. The company's approach to clinical development and licensing strategy for its lead asset will be a key milestone for the firm's evolution.